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Abstract   
Goodpasture’s or anti-glomerular basement membrane (GBM) disease is classically characterised by the 
presence of circulating autoantibodies directed against the non-collagenous domain of the 3 chain of type IV 
collagen(3(IV)NC1), targeting glomerular and alveolar basement membranes, and associated with rapidly 
progressive crescentic glomerulonephritis, with alveolar haemorrhage in over half the patients. However, there 
are increasing examples of variants or atypical presentations of this disease, and proposed novel therapeutic 
options, which nephrologists should be aware of.  The pathophysiology of this condition has been understood 
through molecular analysis of the antibody-antigen interactions and the use of HLA-transgenic animals, while 
the association of anti-GBM antibodies with anti-neutrophil cytoplasm antibodies (ANCA) and their combined 
impact on disease phenotype is increasingly recognised, providing some insights into the basis of glomerular 
damage and autoimmunity.  
 
Introduction 
Goodpasture’s or anti-glomerular basement membrane (GBM) disease is characterised by the presence of 
circulating autoantibodies directed predominantly against the non-collagenous domain of the 3 chain of type 
IV collagen (3(IV)NC1) (1),  found in both glomerular and alveolar basement membranes, resulting in rapidly 
progressive crescentic glomerulonephritis, and alveolar haemorrhage in over half the patients. Although 
uncommon, with an incidence of 0.5- 1.6 cases/million/year (2), approximately 20% of cases of rapidly 
progressive glomerulonephritis (RPGN) are caused by anti-GBM disease, with isolated renal involvement 
occurring in 40% of patients (1). Peak incidence is in the third and sixth decades and there is a male 
preponderance, reflecting increased alveolar haemorrhage in younger men. If untreated, anti-GBM disease is 
life-threatening with irreversible kidney damage and respiratory failure. Since the introduction of modern 
treatment protocols, based on antibody removal by plasma exchange and use of glucocorticoids and 
cyclophosphamide (see table 1), patient outcomes have been transformed (3). Additionally, there has been 
increasing awareness of atypical anti-GBM nephritis and complex clinical variants. Despite the widespread 
availability of diagnostic tests, delayed establishment of the correct diagnosis and thus transfer to treatment 
centres, results in many patients requiring permanent renal replacement th  erapy. In part this is due to the 
rarity of the disease and confounding clinical factors that can potentially explain the cause of AKI, prompting 
physicians to defer performing serological tests. Improving patient outcomes therefore requires increasing 
awareness of the condition and consideration of its variants as well as more urgent diagnostic strategies. For 
example, increasing use of electronic acute kidney injury alerts could prompt more rapid (and automated) 
serological analysis to exclude the diagnosis. This review will highlight recent findings, including environmental 
influences, appreciation of clinical variants and advances in clinical management.  
 Autoantigens  
Type IV collagen contains 6 different subunits, alpha chains (α1 – α6), forming a triple helical structure in the N-
terminal and middle regions, and folding to form a C-terminal globular domain (non-collagenous(NC)1)  (4). 
The main antibody target in anti-GBM disease is α3(IV)NC1 which interacts with the triple helical promoter 
α3α4α5(IV) allowing it to remain cryptic and evade immune surveillance under normal conditions. Denaturing 
conditions disrupt the molecular structure of type IV collagen exposing the antigen and enabling epitope 
recognition, which has been shown to be conformation dependent. Critical amino acid residues were identified 
and immunodominant conformational epitopes characterized by various groups (5, 6), defining the most 
critical as EA and EB (5).  
Predisposing Factors 
Anti-GBM disease is strongly associated with polymorphisms of MHC class II genes, with disease susceptibility 
correlating with Human leukocyte antigen (HLA) DRB1 alleles. DRB1*1501, DRB1*03 and DRB1*04 confer a 
susceptibility for disease while DRB1*01 and DRB1*07 confer a protective effect (7). The molecular basis for 
this HLA effect has in part become clearer following investigations using HLA-transgenic mice, which 
demonstrated that immunodominant 3(IV)NC1 antigens are presented on DR15 susceptibility alleles but not 
on DR1 resistance alleles, and only in DR15 transgenic mice immunized with the 3 peptides, does clinical 
disease develop (8). Susceptibility HLA-DR15 alleles are common in the healthy population, yet disease is rare, 
supporting the notion  that  a second hit in the form of one or more environmental influences is required for 
disease development. Previously suggested triggers have included cigarette smoking or inhaled hydrocarbons, 
damaging the alveolar basement membrane and exposing type IV collagen epitopes(9). Additionally, seasonal 
variation has been reported in small patient cohorts (10, 11) suggesting potential infectious triggers. Spatial 
and temporal clustering of disease incidence at a national level has been recently described (2). Over an 11 year 
period, incidence of anti-GBM disease was 1.6 (range 0.4 to 2.8) per million population per year in Ireland. 
Temporal clustering occurred over a 3 month winter period, supporting previous anecdotal reports and in 
keeping with Ernest Goodpasture’s first description of what he thought was an influenza-related condition (12). 
Lung involvement affected only 20% of the Irish patients, 80% of whom were male, while the majority (72%) 
reached end stage renal failure. Spatial clustering in a rural county was identified, in which none of the 7 
presenting patients had lung disease, but the majority (71%) had detectable anti-GBM antibodies with dual 
positivity for anti-neutrophil cytoplasm antibodies (ANCA)(2). Understanding the HLA allelic variation in this 
region and the exposure to a common environmental influence would be vital to further dissect out disease 
aetiology, while the disproportionate occurrence of dual antibody positivity could represent a difference in 
disease pathogenesis.  
Diagnosis 
Early detection of circulating anti-GBM antibodies in the context of an acute kidney injury, with or without 
pulmonary haemorrhage can direct timely initiation of treatment and improve patient outcome. Many 
physicians are increasingly relying on serology to confirm or refute the diagnosis, feeling that renal biopsy may 
be unnecessary, but there are reasons to be cautious of this approach. Positive anti-GBM serology may be 
occasionally associated with pathology that is pauci-immune (for example in the context of ANCA dual 
positivity, and see atypical cases below), potentially changing the prognosis for renal recovery and propensity 
for relapse. In addition, false positive anti-GBM antibody tests may be found in states of polyclonal activation 
such as in hepatitis C or HIV infection and with diverse renal pathologies. Finally, rare cases of anti-GBM disease 
without circulating anti-GBM antibodies have been reported, which may result in diagnostic delay, until a renal 
biopsy is performed. Serological diagnosis relies on  ELISA or luminex based technologies which have become 
the standard methods for antibody detection using denatured recombinant NC1 portion of α3(IV) as the 
antigenic target.  Specificity and sensitivity of assays have been reported to range from 90 -100% and 94.7 – 
100% respectively (13). However, there are several important variants that need to be considered when 
interpreting anti-GBM antibody results.   
Clinical Variants 
False positive or negative antibody Anti-GBM Disease 
1. Ig class and subclass variants 
IgG1 subclasses are predominantly detected by commercial methods but four subclasses of human IgG exist 
according to their heavy chains (IgG1, IgG2, IgG3 and IgG4) and each can bind to the GBM (14, 15). IgG1 and 
IgG3 subclass restriction is most frequently found in patients both in sera and glomeruli and is more closely 
associated with disease severity; IgG3 has the greatest ability to activate complement and both IgG1 and IgG3 
have the greatest affinity for binding Fc receptors (15, 16). However, IgG4 subclass antibodies have also been 
found to be pathogenic both in isolation and co-existing with other immunoglobulin subclasses in atypical anti-
GBM disease and are not detected by standard ELISA (14, 17). Additionally, IgA anti-GBM antibodies are also 
not detected by standard methods and have been shown to bind various α(IV)chains (including 1,2,5 and 6) 
(18, 19), which may not be represented in standard assays using 3(IV) (Figure 1 ). Antibodies bound to 
glomeruli have a longer half-life than their circulating counterparts and if combined with a low level of antibody 
titer, may make antibody detection in serum difficult (17, 20). Other factors affecting antibody detection can 
include low level antibody affinity and the presence of high levels of circulating polyclonal antibodies 
contributing to false negative or positive results. Finally, rare cases in which circulating anti-GBM antibodies 
may only be detected by highly sensitive techniques such as resonance biosensors have been reported, and it 
remains unclear why these are not picked up on standard assays (21).   
2. Antigen variants 
 Early detection methods used solubilized GBM containing all of the(IV) chains, but modern assays use 
recombinant α3(IV), therefore different antibody target epitopes (contained within 1 or 4(IV) collagen 
chains, or directed against α5 (IV) in cases of Alport nephritis patients developing anti-GBM disease post 
transplantation) may be not be not detected by standard methods . More recently cases of circulating but not 
deposited anti-GBM antibodies have been reported, potentially due to differences in expression of glomerular 
cryptic epitopes not exposed in vivo (Sadeghi-Alavijeh et al, 18th ANCA vasculitis workshop). 
 It is therefore possible to miss a diagnosis of anti-GBM disease based solely on initially ‘negative’ serological 
assays while positive circulating anti-GBM antibodies may not always be associated with linear staining 
crescentic glomerulonephritis, and gold standard immunohistochemical staining of GBM is vital to establish 
the glomerular pathology.  
 ‘Double Positive’ Anti-GBM and ANCA Disease  
The co-existence of anti-neutrophil cytoplasm antibodies (ANCA) with anti-GBM antibodies has been 
increasingly recognised with detection rates varying from 21% to 38% (22-25). In contrast, anti-GBM antibody 
detection in ANCA positive samples has only been found in 8 - 14% of patients (23, 25, 26). Double positive 
patients have broader antigenic specificity, preferential binding of anti-GBM antibodies to α5 chains of type IV 
collagen, and lower levels of  antibodies to α3(NC1)compared to anti-GBM disease alone(27). ANCA directed 
against myeloperoxidase (MPO) predominates in double positive patients with reported frequencies of 66 to 
81% (26, 28).  However, there is greater reactivity to MPO in anti-GBM sera if MPO is deglycosylated (29). Using 
exoglucosidase and endoglucosidase treatment to generate aberrant glycosylated MPOs, more than 50% of 
patients with single anti-GBM antibody positivity demonstrated reactivity to 1 or more aberrant glycosylated 
MPOs, with the greatest rate of detection(over 60%) seen in double positive patients. However, it is worth 
noting that antibodies to aberrant glycosylated MPOs are also seen in a smaller proportion of patients with IgA 
nephropathy, minimal change disease and end-stage renal disease (29).  The clinical significance of these 
observations remains to be clarified. 
 
Double positive patients are affected later in life, somewhat different to anti-GBM disease (median 62 years 
and 44 years respectively) but in keeping with ANCA-associated vasculitis (AAV) (median 65 years) and there 
appears to be a male preponderance (25). Demographic data on the incidence of dual antibody positivity is 
lacking but a single center case series estimated incidence at 0.47 per million people per year (22). Analysis of 
HLA associations in dual positive antibody patients is limited, but HLA DRB1*1501 and DRB1*0405 carriage has 
been reported (30). 
 
Clinical presentation is almost indistinguishable from patients with only anti-GBM antibody positivity but 
clinical course often differs. This is most evident when considering renal recovery. Despite standard 
immunosuppression regimens, dialysis-dependent dual antibody positive patients have reduced renal recovery 
compared with only ANCA positive patients, in keeping with typical anti-GBM disease. In fact, there appears to 
be an inverse relationship between renal recovery and titres of anti-GBM and anti-MPO- antibodies (28). It is 
possible that this may relate to the progression of glomerular lesions where the presence of circulating ANCA 
may cause crescentic lesions of various ages, compared to predominantly acute active lesions in disease 
mediated by anti-GBM antibodies alone (31, 32). Although low in number, relapse in double positive patients 
tends to be associated with subsequent positive ANCA but negative anti-GBM antibody serology, further 
supporting the pathogenic role of ANCA (22, 33).   
 Crescentic Membranous Nephropathy 
Crescent formation in membranous nephropathy is rare and so co-existent anti-GBM disease or ANCA-
associated vasculitis must be considered. The presence of linear immunoglobulin GBM staining and circulating 
anti-GBM antibodies on a background of membranous nephropathy supports the diagnosis of anti-GBM 
disease. However, membranous nephropathy can also occur after the onset of anti-GBM disease in the context 
of glomerular immune complex deposition (34). A single center case series evaluated the clinical, pathological 
and immunological data of 8 patients with membranous nephropathy superimposed on anti-GBM disease with 
particular focus on the co-existence of antibodies to M-type phospholipase A2 receptor (PLA2R) and anti-GBM 
antibodies (35). Clinical features were more in keeping with membranous nephropathy with a higher degree of 
proteinuria, less crescent formation and less severe renal injury compared to anti-GBM disease alone. Antibody 
specificity was narrower with circulating antibodies in all patients recognizing α3(IV)NC1 and minimal reactivity 
to other alpha subunits, unlike age and sex matched anti-GBM disease controls. All patients with membranous 
nephropathy and anti-GBM disease reacted with EA epitope but less so to EB. Whilst IgG4 is implicated in the 
pathogenesis of primary membranous nephropathy, IgG3 and, to a lesser extent, IgG2 were detected on renal 
biopsies in a subset of patients by immunohistochemistry, while serological reactivity to PLA2R was not 
demonstrated and glomerular expression was only detected in 1 patient (36).  
De novo anti-GBM antibody formation that occurs in the context of membranous nephropathy may be due to 
mechanical or inflammatory GBM damage, exposing neo-epitopes and driving autoantibody formation. Sub-
epithelial immune complex deposition and complement activation could disrupt the GBM and promote antigen 
release, and form in situ complexes with exposed GBM antigens (37). The effect of phospholipase A2 receptor 
antibody disrupting the GBM and inducing a conformational change to unveil neo-epitopes may still be 
important.    
 
Anti-GBM following immunotherapy 
The role of regulatory T cells in maintaining and re-stablishing immune tolerance to the autoantigen has been 
suggested as a reason for lack of disease in healthy individuals and paucity of relapses in treated anti-GBM (38) 
, unlike that found in ANCA vasculitis where regulatory cell deficiencies have been identified (39, 40). In keeping 
with this concept, depletional biologic agents that can effectively remove all T cell subsets (Alemtuzumab, anti-
CD52) have been found to trigger de-novo anti-GBM disease (41, 42). Although no other case reports of other 
depletional biologic agents promoting anti-GBM disease have been published, increasing use of biologic agents 
that can alter the balance of effector and regulatory T cell subsets, such as check point inhibitors (anti-PD1, 
anti-CTLA4) may make this more common and should prompt rapid investigation to exclude anti-GBM disease 
in those patients treated with such agents and presenting with rapidly declining renal function and/or  new 
onset urinary abnormalities.  
 Atypical Anti-GBM Nephritis 
The pathological hallmark of anti-GBM disease is linear immunoglobulin GBM staining on 
immunohistochemistry and necrotizing crescentic glomerulonephritis is the characteristic histological lesion. 
However, indolent disease and different patterns of injury with reduced crescent formation may also occur (17). 
In 20 cases identified in a 7 year study period, (accounting for 11.8% of total anti-GBM disease cases) crescent 
formation was only seen in 40% of cases and on average affected only 18% of glomeruli. Fibrinoid necrosis 
affected 7% of glomeruli. Acute tubular necrosis was present in half of cases with mild and focal interstitial 
inflammation in 65%. Segmental membranous nephropathy was seen in 2 patients. Mesangial and/or 
endocapillary hypercellularity occurred in all cases and endocapillary proliferative glomerulonephritis was the 
most common finding. Gold standard immunofluorescence linear IgG GBM staining was seen in 17 patients 
with IgM and IgA binding in the remaining patients. Interestingly, the presence of crescent formation was more 
commonly associated with polytypic IgG antibody profiles (deposits staining for both kappa and lambda light 
chains) compared to monotypic binding. Renal recovery and patient outcomes were better than typical anti-
GBM disease, likely due to the pattern of renal injury but also the absence of lung involvement in this cohort 
(17). Finally, a number of dual positive (ANCA and anti-GBM) patients appear to have a predominant pauci-
immune glomerulonephritis with relatively good rates of renal recovery.  
 
Management 
Antibody removal 
The main goals of therapy in anti-GBM disease are rapid removal of circulating anti-GBM antibodies and 
suppression of autoantibody formation. This is most commonly achieved using plasma exchange and 
immunosuppression (glucocorticoids and cyclophosphamide) respectively. Timely initiation of treatment is 
critical as renal recovery is much more likely in the early phase of disease, for example before oliguria or dialysis-
dependency occurs. A treatment regimen historically established by the Hammersmith group remains at the 
forefront of therapy (Table 1). Prednisolone (1mg/kg tapered over 6-9 months) and cyclophosphamide for 2 – 
3 months are used in combination with daily plasmapheresis for 14 days, or until the anti-GBM antibody is no 
longer detectable (3, 43). This approach has transformed patient and kidney survival. Long-term follow-up of 
patients requiring dialysis at presentation found patient and kidney survival to be 65% and 8% respectively at 1 
year and 44% and 13% at 5 years. However, in patients not requiring dialysis, patient and kidney survival at 1 
year was reported to be 100% and 95% respectively and both 94% at 5 years (43).  
 
Despite overwhelming evidence outlining the benefits of immunosuppression and plasma exchange, most 
reported studies are uncontrolled with only a single randomized prospective study conducted to date (44). 
Nevertheless, over a 5 year period Johnson et al showed that immunosuppression (oral prednisolone 2 mg/kg 
daily for 1 week; oral cyclophosphamide 2mg/kg daily for 3 months tapering to 1mg/kg) in combination with 
plasma exchange every 3 days (compared to daily therapy described in the Hammersmith treatment regimen) 
was more effective than immunosuppression alone. Although not well matched for severity of renal injury at 
presentation, measured by percentage of crescentic lesions and serum creatinine, which was a clear prognostic 
factor, adjunctive plasma exchange improved outcome. Anti-GBM antibodies were more rapidly removed 
when immunosuppression and plasma exchange were combined and this was associated with better renal 
recovery, measured by serum creatinine and dialysis requirement (44). A large retrospective study supported 
these findings with improved patient and kidney outcome in patients treated with immunosuppression and 
plasma exchange compared to those treated with immunosuppression alone (45). 
 
Although plasma exchange is an invasive procedure with potential complications relating to venous access, and 
reactions to replacement fluid,  it is generally well-tolerated and only associated with minor complications (46). 
Albumin is the replacement fluid of choice but fresh frozen plasma (FFP) has to be added in some patients, if 
there is a bleeding risk, for example  after renal biopsy, or in patients with pulmonary haemorrhage. FFP is 
typically collected in anticoagulant citrate dextrose solution (ACD) and so must be exchanged at a lower rate 
than albumin; bicarbonate production and reduced renal excretion after citrate metabolism poses a risk of 
metabolic alkalosis (47).  
 
Immunoadsorption (IAS) is an alternative method of removing antibody from the circulation and is used in the 
treatment of several autoimmune diseases. In renal disease, IAS is most frequently used in ABO incompatible 
and highly sensitized renal transplant recipients, in antibody-mediated rejection, and in SLE (using DNA-
binding columns) while advocates have proposed IAS as a therapy in other glomerular disease, notably focal 
segmental glomerular sclerosis, ANCA-associated vasculitis and anti-GBM disease (48). IAS has additional 
benefits to plasma exchange, including selective high affinity binding of IgG subclasses 1, 2 and 4 (but variable 
binding of IgG 3, IgA and IgM), requires no FFP or albumin and allows a greater plasma volume to be processed. 
Processing of 2.5 plasma volumes has the capacity to remove up to 87% IgG, with multiple sessions increasing 
IgG clearance to >98% (48).  
 
The role of IAS in anti-GBM disease has not been widely evaluated with only case reports described prior to a 
retrospective review of 10 patients treated with IAS and immunosuppression. Antibody levels were 71 to 84% 
lower after the first IAS treatment and were within normal range after 2 – 9 treatments (49). Long-term patient 
and kidney survival was reported to be 90% and 50% respectively at a mean of 84 months, somewhat better 
than previous reports using plasma exchange and immunosuppression but not comparable to larger patient 
cohorts (43). Therefore, IAS offers an effective therapy for direct removal of circulating anti-GBM antibodies 
and is non-inferior to plasma exchange although this needs to be more thoroughly evaluated.  
 
Plasma exchange and IAS can remove circulating but not tissue-bound anti-GBM antibodies. This problem can 
be targeted by virtue of the properties of bacterial proteins secreted by Streptococus pyogenes, specifically IgG-
degrading enzyme of S.pygoenes (IdeS) and endoglycosidase S (EndoS). IdeS cleaves the heavy chain of human 
IgG resulting in one F(ab’)2 and two monomeric Fc fragments thereby directly affecting IgG effector functions. 
In comparison, endoglycosidase hydrolysis of all IgG subclass glycans diminishes C1q binding and complement 
activation as well as IgG-mediated opsonization by impairing IgG FcγR binding. IgM and IgA are resistant to 
both enzymatic activities (50).  
The efficacy of IdeS and EndoS degradation of circulating autoantibodies (51, 52) and tissue-bound anti-GBM 
antibodies has been shown (53). In an experimental murine model of glomerulonephritis, IdeS removed 
glomerular Fc fragments of anti-GBM antibodies and was associated with a reduction in leukocyte infiltrate and 
complement activation as well as complete prevention of albuminuria. This effect was not seen with EndoS 
treatment even although albuminuria was reduced (53). Following safety studies (54), IdeS trials have 
progressed mainly in kidney transplantation, but a clinical trial is also underway in anti-GBM disease, evaluating 
the efficacy of IdeS in removing pathogenic tissue-bound anti-GBM antibodies (GOODIdeS). 
 
Immunosuppression 
Glucocorticoids and cyclophosphamide continue to be the mainstay of immunosuppressive treatment in anti-
GBM disease. However, there are circumstances where alternative agents may be required most likely relating 
to the potential risks and tolerability of cyclophosphamide. Rituximab has been used in this instance with good 
effect, albeit described only in up to twenty case reports (55). Mycophenolate mofetil has also been used, again 
described only in a handful of case reports but appears to be beneficial in refractory or relapsing disease (56-
58). In all cases duration of therapy after induction treatment is unclear and is directed by clinical symptoms 
and achieving persistently negative anti-GBM antibodies.  In cases in whom renal recovery is deemed unlikely 
(oligoanuria, dialysis dependent with 100% crescents on renal biopsy) and there is no associated pulmonary 
haemorrhage, immunosuppression may be avoided.  However, rare cases of renal recovery despite dialysis 
dependency have been reported, in which kidney injury may have a significant contribution from severe tubular 
injury or milder glomerular damage (59, 60). Anti-GBM antibodies will disappear naturally over two years on 
average. In cases where potential living kidney donors are forthcoming, more rapid antibody removal may be 
warranted to allow earlier transplantation. We have used both rituximab and cyclophosphamide in these cases 
and rates of antibody decline appear similar, however, they are significantly faster when combined with 
plasmapheresis. Although no comparison trials are available we suggest six months of anti-GBM antibody 
negativity prior to transplantation, and this strategy has resulted in no cases of recurrent disease in our 
transplant populations, although very rare cases have previously been reported (61) in which other provoking 
factors may have contributed.  
 
Conclusion 
There are clearly challenging clinical variants of anti-GBM disease. Recognizing different patterns of disease 
and therefore understanding mechanism of injury is more complex. Increasing awareness of different 
pathogenic immunoglobulin classes and subclasses as well as antigen specificities can make interpreting 
immunological findings difficult. The archetypal crescentic glomerulonephritis with linear antibody deposition 
may not always be present making clinical diagnosis even more problematic. However, the principles in 
management remain the same; rapid removal of pathogenic antibodies and prevention of their re-synthesis. 
Whilst direct removal of circulating antibodies by plasma exchange, or perhaps immunoadsorption, are very 
effective, there are potential new therapies which may also target tissue-bound antibodies persisting in 
glomeruli and driving disease.  
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Table 1 
 
Current treatment protocols Potential variants without substantial cohort 
evidence to date (see text) 
1. Glucocorticoids 
1mg/Kg Prednisolone/day; max 60 mg; tapering 
weekly 45mg, 30 mg, 25, 20 mg; followed by  
slower taper(2.5 mg /fortnight) up to month 6 
2. Immunosuppression 
Oral cyclophosphamide 2-3 mg/Kg, adjusted for 
WCC (to keep above 4). Reduced dose in elderly 
(1.5-2mg). 3 months of treatment, possibly 
shorter in elderly if adequate clinical and 
immunological response.  
 
3. Plasma exchange 
60 mls/Kg, max 4 litres, daily for 14 days or until 
anti-GBM titre normalized. Using 5% human 
albumin alone with additional FFP if risk of 
bleeding (recent invasive procedure or 
pulmonary haemorrhage).  
4. Prophylaxis 
Co-trimoxazole (or in case of intolerance 
Dapsone, or monthly pentamidine); 
Anti-fungal( nystatin  or fluconazole) 
Proton pump inhibitor or H2 antagonist 
Calcium/vitamin D 
 
 
 
 
 
 
 
IV cyclophosphamide as per ANCA vasculitis 
protocol, care in timing with plasma exchange, 
give after Plasma exchange(Pex) session and 
wait 24 hours, before next Pex. 
Rituximab 1g x 2 doses 
 
 
Immunoadsorption 
IdeS therapy  
 
 
 
 
 
 
  
Figure 1 
 
Figure 1 – Renal biopsy tissue from a patient with IgA anti-GBM disease stained with haematoxylin and eosin 
(A) and by immunohistochemistry for IgG (B) and IgA (C)(all x400). A large circumferential cellular crescent is 
present in the glomerulus and is associated with compression of the glomerular tuft (A). Linear glomerular 
basement membrane IgG is not seen by immunohistochemistry (B) but linear IgA (C) is demonstrated within 
the crescentic lesion.  
 
 
